Adipogenic Stimulation and Pyrrolidine Dithiocarbamate Induced Osteogenic Inhibition of Dental Pulp Stem Cells Is Countered by Cordycepin.
cordycepin
dental pulp stem cells
osteogenesis
regeneration
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
14 Sep 2021
14 Sep 2021
Historique:
received:
29
07
2021
revised:
09
09
2021
accepted:
10
09
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
dental pulp-derived stem cells are easy to access and collect and are an excellent source of stem cells for regenerative therapy. These cells can interact with many biomolecules and scaffolds and can pass on the instructive signals to the sites of regeneration where they are used. In this regard cordycepin, a potential biomolecule derived from medicinal mushrooms with a spectrum of bioactive properties such as antioxidant, anti-inflammatory, and anticancer has not yet been tested for its effect on human dental pulp stem cells. the objective of the present study was to assess the in vitro adipogenic and osteogenic differentiation potential of human dental pulp stem cells with or without induction after administration of cordycepin. human dental pulp stem cells DPSCs were isolated from a healthy permanent tooth extracted for orthodontic purposes after obtaining informed consent. Flow cytometry technique was used to assess the surface markers of these cells such as CD73, CD90, and CD105, CD34, CD45, and HLA-DR. Further, an MTT assay was performed on the cells after subjecting them to various concentrations of cordycepin. Following this, the adipogenic and osteogenic potential of the dental pulp stem cells was assessed with or without induction under the influence/absence of 5 µM of cordycepin. The results obtained were statistically analyzed and documented. it was found that the dental pulp stem cells showed strong positive expression for CD73, CD90, and CD105 and faint expression of CD34, CD45, and HLA-DR. MTT assay revealed that 5 µM was the optimum concentration of cordycepin for all the assays. Concerning adipogenesis experiments, there was a statistically significant lowering of all the 4 adipogenesis-related genes PPARγ, FABP4, LPL, and C/EBPα following cordycepin treatment in the presence of induction compared to the only induction group and untreated control cells ( cordycepin can be exploited for its osteopromotive properties and can be used as a bioactive molecule alongside the administration of dental pulp stem cells in the area of regenerative biology and medicine.
Sections du résumé
BACKGROUND
BACKGROUND
dental pulp-derived stem cells are easy to access and collect and are an excellent source of stem cells for regenerative therapy. These cells can interact with many biomolecules and scaffolds and can pass on the instructive signals to the sites of regeneration where they are used. In this regard cordycepin, a potential biomolecule derived from medicinal mushrooms with a spectrum of bioactive properties such as antioxidant, anti-inflammatory, and anticancer has not yet been tested for its effect on human dental pulp stem cells.
OBJECTIVE
OBJECTIVE
the objective of the present study was to assess the in vitro adipogenic and osteogenic differentiation potential of human dental pulp stem cells with or without induction after administration of cordycepin.
MATERIALS AND METHODS
METHODS
human dental pulp stem cells DPSCs were isolated from a healthy permanent tooth extracted for orthodontic purposes after obtaining informed consent. Flow cytometry technique was used to assess the surface markers of these cells such as CD73, CD90, and CD105, CD34, CD45, and HLA-DR. Further, an MTT assay was performed on the cells after subjecting them to various concentrations of cordycepin. Following this, the adipogenic and osteogenic potential of the dental pulp stem cells was assessed with or without induction under the influence/absence of 5 µM of cordycepin. The results obtained were statistically analyzed and documented.
RESULTS
RESULTS
it was found that the dental pulp stem cells showed strong positive expression for CD73, CD90, and CD105 and faint expression of CD34, CD45, and HLA-DR. MTT assay revealed that 5 µM was the optimum concentration of cordycepin for all the assays. Concerning adipogenesis experiments, there was a statistically significant lowering of all the 4 adipogenesis-related genes PPARγ, FABP4, LPL, and C/EBPα following cordycepin treatment in the presence of induction compared to the only induction group and untreated control cells (
CONCLUSION
CONCLUSIONS
cordycepin can be exploited for its osteopromotive properties and can be used as a bioactive molecule alongside the administration of dental pulp stem cells in the area of regenerative biology and medicine.
Identifiants
pubmed: 34575692
pii: jpm11090915
doi: 10.3390/jpm11090915
pmc: PMC8468365
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Immunopathol Pharmacol. 2015 Sep;28(3):296-307
pubmed: 26130747
Stem Cell Rev. 2008 Spring;4(1):21-6
pubmed: 18300003
Phytother Res. 2020 Oct 8;:
pubmed: 33090621
J Pharm Pharmacol. 2019 Sep;71(9):1429-1439
pubmed: 31259423
Stem Cell Rev Rep. 2016 Oct;12(5):511-523
pubmed: 27240827
Int Endod J. 2011 Sep;44(9):800-6
pubmed: 21477154
3 Biotech. 2014 Feb;4(1):1-12
pubmed: 28324458
Calcif Tissue Int. 1999 Jan;64(1):1-7
pubmed: 9868276
J Tissue Eng Regen Med. 2008 Jun;2(4):169-83
pubmed: 18493906
Nat Prod Commun. 2011 Dec;6(12):1839-41
pubmed: 22312720
Int J Cell Biol. 2016;2016:6940283
pubmed: 27516776
Nature. 2001 Nov 1;414(6859):118-21
pubmed: 11689957
Molecules. 2020 Jun 12;25(12):
pubmed: 32545666
Appl Biochem Biotechnol. 2009 Aug;158(2):483-92
pubmed: 19247587
Clin Exp Pharmacol Physiol. 2004 Dec;31 Suppl 2:S51-3
pubmed: 15649290
Br J Pharmacol. 2012 Oct;167(3):561-75
pubmed: 22537056
Front Immunol. 2014 Feb 13;5:48
pubmed: 24592264
Oncotarget. 2015 Nov 3;6(34):35496-508
pubmed: 26462178
Curr Opin Rheumatol. 2018 Jan;30(1):59-64
pubmed: 29016371
Biomed Pharmacother. 2020 May;125:109991
pubmed: 32084699